Loading
A phase 1/2 trial of Divarasib, Pembrolizumab, Carboplatin in non-small-cell lung cancer, run by Hoffmann-La Roche, now recruiting.
A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation is a phase 1/2 interventional study registered as NCT05789082 by Hoffmann-La Roche, with 320 participants planned, started 2023-06-20 and due to reach its primary completion in 2032-01-29. Interventions recorded: Divarasib, Pembrolizumab, Carboplatin, Cisplatin, Pemetrexed. Conditions listed: Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Divarasib, KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors, Roche / Genentech.
Shares Divarasib, KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors, Roche / Genentech.
Shares KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors, Pemetrexed, Cisplatin.
Shares KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors, Pemetrexed, Cisplatin.
Shares KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors, Pemetrexed, Cisplatin.
Shares Divarasib, KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors, Roche / Genentech.
Shares KRAS & RAS inhibitors, Pemetrexed, Cisplatin, Carboplatin.
Shares Pemetrexed, Cisplatin, Carboplatin, Pembrolizumab.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/